{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:59:21Z","timestamp":1783468761305,"version":"3.55.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with myasthenia gravis (MG) display strong treatment heterogeneity. Recent studies have indicated that low-dose steroids or immunosuppressants are effective. However, factors affecting the add-on of non-corticosteroid immunosuppressants to corticosteroids remain unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Consecutive patients with MG were retrospectively reviewed from May 15, 2015, to December 29, 2020. We included one group of patients with steroid treatment alone and another group who transitioned to non-steroid immunosuppressant therapy. Clinical features of the included patients were analyzed. Univariate and multivariate Cox regression models were used to identify potential influential factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 107 patients with MG were analyzed, including 66 receiving corticosteroid treatment alone and 41 who subsequently also received non-corticosteroid immunosuppressant therapy. Eight potential factors were primarily selected in univariate analysis (Ps\u2009&amp;lt;\u20090.1). Achieving minimal symptom expression (MSE) within 6\u2009months (HR: 4.424, 95%CI: 2.102\u201311.865), body mass index (BMI) (HR: 0.385, 95% CI: 0.186\u20130.797), quantitative MG (QMG) bulbar muscle score (HR: 1.553, 95% CI: 1.140\u20132.118), disease duration (HR: 0.987, 95% CI: 0.977\u20130.997) and relapse (HR: 2.638, 95% CI: 1.031\u20136.750) were finally identified as potential influencing factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We found multifactorial clinical factors were highly associated with the add-on of non-steroid immunosuppressants after steroid treatment in patients with MG. Achieving MSE within 6\u2009months, BMI, QMG bulbar muscle score at baseline before steroid treatment, disease duration, and disease relapse may represent crucial influencing factors, which should be considered to improve the long-term prognosis for patients with MG in future studies and practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1474508","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:10:30Z","timestamp":1730869830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiaojiao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongtai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and Management of Seronegative Myasthenia Gravis: lights and shadows","volume":"13","author":"Vinciguerra","year":"2023","journal-title":"Brain Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/brainsci14080774","article-title":"Effectiveness and safety of Mycophenolate Mophetil in myasthenia gravis: a real-life multicenter experience","volume":"14","author":"Vinciguerra","year":"2024","journal-title":"Brain Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/wnl.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1976","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2017-316625","article-title":"Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan","volume":"89","author":"Imai","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s10072-022-05897-0","article-title":"Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","article-title":"Course and management of myasthenia gravis","volume":"153","author":"Grob","year":"1953","journal-title":"J Am Med Assoc"},{"key":"ref26","first-page":"216","article-title":"Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and the early part of 1932","volume":"37","author":"Kennedy","year":"1937","journal-title":"Can Med Assoc J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10072-017-3194-0","article-title":"Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis","volume":"39","author":"Sciacca","year":"2018","journal-title":"Neurol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mus.1140","article-title":"Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert\u2010Eaton myasthenic syndrome","volume":"24","year":"2001","journal-title":"Muscle Nerve"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13760-022-02162-1","article-title":"Minimal symptom expression achievement over time in generalized myasthenia gravis","volume":"123","author":"Uzawa","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"816243","DOI":"10.3389\/fneur.2022.816243","article-title":"Clinical predictors of relapse in a cohort of steroid-treated patients with well-controlled myasthenia gravis","volume":"13","author":"Su","year":"2022","journal-title":"Front Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1046\/j.1440-6047.11.s8.9.x","article-title":"Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults","volume":"15","author":"Zhou","year":"2002","journal-title":"Biomed Environ Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666x.2021.1936500","article-title":"Heterogeneity in myasthenia gravis: considerations for disease management","volume":"17","author":"Evoli","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9138548","article-title":"Tacrolimus as single-agent immunotherapy and minimal manifestation status in Nonthymoma myasthenia gravis","volume":"2021","author":"Duan","year":"2021","journal-title":"J Immunol Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e16400","DOI":"10.1097\/md.0000000000016400","article-title":"Obesity in psoriatic arthritis: comparative prevalence and associated factors","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e13401","DOI":"10.1111\/obr.13401","article-title":"Variation in glucocorticoid sensitivity and the relation with obesity","volume":"23","author":"Lengton","year":"2022","journal-title":"Obes Rev"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/jpm11111139","article-title":"Assessment of sarcopenia and obesity in patients with myasthenia gravis using dual-energy X-ray absorptiometry: a cross-sectional study","volume":"11","author":"Chang","year":"2021","journal-title":"J Pers Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1210\/en.2006-0687","article-title":"Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes","volume":"148","author":"Lacasa","year":"2007","journal-title":"Endocrinology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/cells10102602","article-title":"Adipose tissue steroid receptor RNA activator 1 (SRA1) expression is associated with obesity, insulin resistance, and inflammation","volume":"10","author":"Kochumon","year":"2021","journal-title":"Cells"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.Wnl.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"17562864221080520","DOI":"10.1177\/17562864221080520","article-title":"Factors affecting minimal manifestation status induction in myasthenia gravis","volume":"15","author":"Li","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1093\/ejcts\/ezt641","article-title":"Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis","volume":"45","author":"Leuzzi","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/mus.25052","article-title":"Remission and relapse of myasthenia gravis on long-term azathioprine: an ambispective study","volume":"54","author":"Gupta","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0303-8467(90)90057-c","article-title":"Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects","volume":"92","author":"Antonini","year":"1990","journal-title":"Clin Neurol Neurosurg"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref61","volume-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","year":"2000"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1474508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:10:34Z","timestamp":1730869834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1474508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":61,"alternative-id":["10.3389\/fneur.2024.1474508"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1474508","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"1474508"}}